Skip to content
10-K

Annual Report

ABIOMED INC

0001564590-21-029314

← back to feed
Filed
May 21, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2021 · May 14, 2021 45.3M sh
Eps Diluted FY 2021 · Mar 31, 2021 $1.24
Eps Diluted FY 2021 · Dec 31, 2020 $1.35
Eps Diluted FY 2021 · Sep 30, 2020 $1.36
Eps Diluted FY 2021 · Jun 30, 2020 $0.98
Eps Diluted FY 2021 · Mar 31, 2020 $0.70
Eps Diluted FY 2021 · Dec 31, 2019 $1.51
Eps Diluted FY 2021 · Sep 30, 2019 $0.28
Eps Diluted FY 2021 · Jun 30, 2019 $1.93
Eps Diluted FY 2021 · Mar 31, 2019 $5.61
Eps Basic FY 2021 · Mar 31, 2021 $1.26
Eps Basic FY 2021 · Dec 31, 2020 $1.37
Eps Basic FY 2021 · Sep 30, 2020 $1.38
Eps Basic FY 2021 · Jun 30, 2020 $0.99
Eps Basic FY 2021 · Mar 31, 2020 $0.71
Eps Basic FY 2021 · Dec 31, 2019 $1.53
Eps Basic FY 2021 · Sep 30, 2019 $0.29
Eps Basic FY 2021 · Jun 30, 2019 $1.97
Eps Basic FY 2021 · Mar 31, 2019 $5.77
Net Income FY 2021 · Mar 31, 2021 $56.86M
Net Income FY 2021 · Dec 31, 2020 $61.87M
Net Income FY 2021 · Sep 30, 2020 $62.21M
Net Income FY 2021 · Jun 30, 2020 $44.59M
Net Income FY 2021 · Mar 31, 2020 $31.8M
Net Income FY 2021 · Dec 31, 2019 $69.22M
Net Income FY 2021 · Sep 30, 2019 $13.07M
Net Income FY 2021 · Jun 30, 2019 $88.92M
Net Income FY 2021 · Mar 31, 2019 $259.02M
Revenue FY 2021 · Mar 31, 2021 $241.25M
Revenue FY 2021 · Dec 31, 2020 $231.66M
Revenue FY 2021 · Sep 30, 2020 $209.76M
Revenue FY 2021 · Jun 30, 2020 $164.85M
Revenue FY 2021 · Mar 31, 2020 $206.66M
Revenue FY 2021 · Dec 31, 2019 $221.58M
Revenue FY 2021 · Sep 30, 2019 $204.97M
Revenue FY 2021 · Jun 30, 2019 $207.67M
Revenue FY 2021 · Mar 31, 2019 $769.43M
Cash And Equivalents FY 2021 · Mar 31, 2020 $192.34M
Current Liabilities FY 2021 · Mar 31, 2020 $131.89M
Total Liabilities FY 2021 · Mar 31, 2020 $151M
Current Assets FY 2021 · Mar 31, 2020 $635.86M
Total Assets FY 2021 · Mar 31, 2020 $1.22B
Shares Diluted FY 2021 · Mar 31, 2019 46.15M sh
Capex FY 2021 · Mar 31, 2019 $44M
Operating Cash Flow FY 2021 · Mar 31, 2019 $252.2M
Sga Expense FY 2021 · Mar 31, 2019 $321.55M
Rd Expense FY 2021 · Mar 31, 2019 $93.5M
Operating Income FY 2021 · Mar 31, 2019 $224.81M
Stockholders Equity FY 2021 · Mar 31, 2018 $689.52M